The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MARC-2: An open-label trial to characterize patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of the first VEGFR-TKI therapy.
Michael D. Staehler
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Expert Testimony - Novartis
Lothar Bergmann
Consultant or Advisory Role - Renal Cell Cancer; Renal Cell Cancer
Honoraria - Renal Cel cancer; Renal Cel cancer
Viktor Grünwald
Consultant or Advisory Role - Are; Areo; Bayer; Bayer; GlaxoSmithKline; GlaxoSmithKline; Novartis; Novartis; Pfizer; Pfizer; Roche; Roche
Honoraria - GlaxoSmithKline; GlaxoSmithKline; Novartis; Novartis; Pfizer; Pfizer
Research Funding - Pfizer; Pfizer
Torsten Huschke
No relevant relationships to disclose
Ulrich Keilholz
Research Funding - Novartis
Carsten Henning Ohlmann
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Expert Testimony - Novartis
Michael Stöckle
No relevant relationships to disclose
Karin Weigang-Koehler
No relevant relationships to disclose
Kirsten Hauswald
No relevant relationships to disclose
Felix Schaller
No relevant relationships to disclose
Luise Strassl
No relevant relationships to disclose
Kerstin Junker
No relevant relationships to disclose